Viloxazine extended-release shows promise for treating adults with ADHD who also experience symptoms of depression and anxiety.
n = 345 adults seeking web based ADHD assessment (predominantly female; mean age = 35). Sensitivity = 80.6% and Positive Predictive Value = 94.9%. False positive rate = 12% versus 56% for the clinical ...
Understanding clinical heterogeneity in attention deficit hyperactivity disorder (ADHD) is important for improving personalized care and long-term outcomes. A study exploits the large scale and ...
The team at Akili describes its ethos on its website as “establishing a new era of cognitive medicine.” The company writes it “[believes] effective medicine can also be fun and engaging [by] creating ...
In your book, you state that these 12 steps can be adapted for individual therapy. Is there a difference in the efficacy of group cognitive-behavioral therapy versus individual cognitive-behavioral ...
CNS stimulants vs nonstimulants may yield better clinical outcomes for adolescents and young adults with ADHD and comorbid depression.
Attention deficit-hyperactivity disorder occurs in adults as well as children, but engaging adults in treatment and ensuring adherence to therapy present specific challenges. As medication options ...
Drugs for Attention Deficit Hyperactive Disorder (ADHD) treatment Researchers compare viloxazine as a nonstimulant treatment option to atomoxetine for managing inattention, hyperactivity, and ...
They conducted a six-week, multicenter, randomized clinical trial with 53 adults aged 18 to 65 who had been diagnosed with ADHD. Participants were randomly assigned to receive either a 20 μg dose of ...
n = 345 adults seeking web-based ADHD assessment (predominantly female; mean age = 35) Sensitivity = 80.6% and Positive Predictive Value = 94.9% False-positive rate = 12% versus 56% for the in-person ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results